Could local delivery of bisphosphonates be a new therapeutic choice for hemangiomas?

Medical Hypotheses

Volumn 73, Issue 4, 2009, Pages 495-497

  Yu, Hejun ^a   Qin, An ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM PHOSPHATE CERAMIC; CLODRONIC ACID; CORTICOSTEROID; FIBROBLAST GROWTH FACTOR 2; PAMIDRONIC ACID; PROPRANOLOL; VASCULOTROPIN; VINCRISTINE; ZOLEDRONIC ACID;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE METASTASIS; BONE TUMOR; BREAST CANCER; CANCER INHIBITION; CONTROLLED RELEASE FORMULATION; DECREASED APPETITE; DRUG DELIVERY SYSTEM; DRUG MECHANISM; EYE INFLAMMATION; GASTROINTESTINAL IRRITATION; GASTROINTESTINAL SYMPTOM; GROWTH RETARDATION; HEMANGIOMA; HUMAN; JAW OSTEONECROSIS; METASTASIS INHIBITION; MOON FACE; NEUROTOXICITY; OSTEOPOROSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; SLEEP DISORDER; SOLID TUMOR; VASCULAR ENDOTHELIUM;

BRAIN NEOPLASMS; CALCIUM PHOSPHATES; DIPHOSPHONATES; DRUG DELIVERY SYSTEMS; HEMANGIOMA; HUMANS;

EID: 69349102074     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.06.015     Document Type: Article

References (34)

1. Holmdahl K. Cutaneous hemangiomas in premature and mature infants. Acta Paediatr 44 4 (1955) 370-379
2. Jacobs A.H. Strawberry hemangiomas; the natural history of the untreated lesion. Calif Med 86 1 (1957) 8-10
3. Mulliken J.B., and Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg 69 3 (1982) 412-422
4. Boscolo E., and Bischoff J. Vasculogenesis in infantile hemangioma. Angiogenesis (2009)
5. Iwata J., et al. High frequency of apoptosis in infantile capillary haemangioma. J Pathol 179 4 (1996) 403-438
6. Razon M.J., et al. Increased apoptosis coincides with onset of involution in infantile hemangioma. Microcirculation 5 2-3 (1998) 189-195
7. Jackson R. The natural history of strawberry naevi. J Cutan Med Surg 2 3 (1998) 187-189
8. Dinehart S.M., Kincannon J., and Geronemus R. Hemangiomas: evaluation and treatment. Dermatol Surg 27 5 (2001) 475-485
9. Kushner B.J. Hemangiomas in children. N Engl J Med 341 26 (1999) 2018-2019
10. Fost N.C., and Esterly N.B. Successful treatment of juvenile hemangiomas with prednisone. J Pediatr 72 3 (1968) 351-357
11. Gampper T.J., and Morgan R.F. Vascular anomalies: hemangiomas. Plast Reconstr Surg 110 2 (2002) 572-585 quiz 586; discussion 587-8
12. White C.W., et al. Treatment of childhood angiomatous diseases with recombinant interferon alfa-2a. J Pediatr 118 1 (1991) 59-66
13. Ezekowitz R.A., Mulliken J.B., and Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 326 22 (1992) 1456-1463
14. Folkman J., Browder T., and Palmblad J. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost 86 1 (2001) 23-33
15. Bauland C.G., et al. The pathogenesis of hemangiomas: a review. Plast Reconstr Surg 117 2 (2006) 29e-35e
16. Chang J., et al. Proliferative hemangiomas: analysis of cytokine gene expression and angiogenesis. Plast Reconstr Surg 103 1 (1999) 1-9 discussion 10
17. Takahashi K., et al. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 93 6 (1994) 2357-2364
18. Fournier P. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62 22 (2002) 6538-6544
19. Wood J., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302 3 (2002) 1055-1061
20. Nagai T., et al. Antiangiogenic effects of bisphosphonates on laser-induced choroidal neovascularization in mice. Invest Ophthalmol Vis Sci 48 12 (2007) 5716-5721
21. Dass C.R., Tran T.M., and Choong P.F. Angiogenesis inhibitors and the need for anti-angiogenic therapeutics. J Dent Res 86 10 (2007) 927-936
22. Meunier P.J., et al. Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone. Lancet 2 8141 (1979) 489-492
23. Delmas, et al. Long term effects of dichloromethylene diphosphonate in Paget's disease of bone. J Clin Endocrinol Metab 54 4 (1982) 837-844
24. Hashimoto K., et al. Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells. Biochem Biophys Res Commun 354 2 (2007) 478-484
25. Bezzi M., et al. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem 278 44 (2003) 43603-43614
26. Luckman S.P., et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13 4 (1998) 581-589
27. Santini D., et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 8 5 (2002) 1080-1084
28. Vincenzi B., et al. Bisphosphonates: new antiangiogenic molecules in cancer treatment?. Ann Oncol 4 5 (2003) 806-807
29. Ferretti G., et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 69 1 (2005) 35-43
30. Lambrinoudaki I., Christodoulakos G., and Botsis D. Bisphosphonates. Ann N Y Acad Sci 1092 (2006) 397-402
31. Denissen H., et al. Net-shaped hydroxyapatite implants for release of agents modulating periodontal-like tissues. J Periodontal Res 32 1 Pt 1 (1997) 40-46
32. Piattelli A., Scarano A., and Mangano C. Clinical and histologic aspects of biphasic calcium phosphate ceramic (BCP) used in connection with implant placement. Biomaterials 17 18 (1996) 1767-1770
33. Faucheux C., et al. Controlled release of bisphosphonate from a calcium phosphate biomaterial inhibits osteoclastic resorption in vitro. J Biomed Mater Res A 89 1 (2009) 46-56
34. Josse S., et al. Novel biomaterials for bisphosphonate delivery. Biomaterials 26 14 (2005) 2073-2080